ArticleFrontiers in oncology2026
Case Report: Cerebellar ALK+ ALCL: diagnostic challenges and therapeutic innovation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) of the central nervous system (CNS) is an exceedingly rare T-cell malignancy, with only a few adult cases reported worldwide. To our knowledge, this represents the first reported adult case of cerebellar ALK+ ALCL from China, highlighting both diagnostic challenges and therapeutic innovations in neuro-oncology. We present a 35-year-old male with subacute cerebellar syndrome initially misdiagnosed as infectious encephalitis due to overlapping clinical, radiological, and cerebrospinal fluid (CSF) findings. Progressive neurological deterioration despite empiric antimicrobial therapy prompted histopathological evaluation, which confirmed ALK+ ALCL with a high Ki-67 index (60%). Targeted therapy with the CNS-penetrant ALK inhibitor alectinib induced rapid clinical improvement and significant radiographic regression. This case highlights the diagnostic pitfalls of CNS ALCL, emphasizes the necessity of early biopsy in atypical lesions, and demonstrates the transformative potential of molecularly targeted therapies for rare neuro-oncological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.